Skip to main content
Clinical Trials/ISRCTN38126962
ISRCTN38126962
Completed
未知

ANDREA-LD: ANti-psychotic Drug REduction in primary care for Adults with Learning Disabilities (ANDREA-LD): a randomised double-blind placebo-controlled trial

Cardiff University (UK)0 sites310 target enrollmentApril 8, 2013

Overview

Phase
未知
Intervention
Not specified
Conditions
earning disabilities
Sponsor
Cardiff University (UK)
Enrollment
310
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

Registry
who.int
Start Date
April 8, 2013
End Date
June 30, 2016
Last Updated
7 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Cardiff University (UK)

Eligibility Criteria

Inclusion Criteria

  • 1\. Aged 18 or over
  • 2\. Have a learning disability as judged by administrative classification (e.g. on practice learning disability register, in receipt of an annual learning disability health check, in receipt of learning disability services) and a score on the Adaptive Behaviour Scale that converts to an estimated IQ of 70 or below using the method described by Moss and Hogg
  • 3\. Currently prescribed one of two anti\-psychotic drugs, haloperidol or risperidone, for treatment of challenging behaviour

Exclusion Criteria

  • 1\. Current diagnosis of psychosis
  • 2\. Known recurrence of psychosis following previous drug reduction in the past 3 years
  • 3\. The clinician responsible for their treatment judges for any other reason that the participation in a drug reduction programme may be counter\-indicated.

Outcomes

Primary Outcomes

Not specified

Similar Trials